Related Experiment Video
Updated: May 29, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
173
Semaglutide: Double-edged Sword with Risks and Benefits.
Lekha Pillarisetti1, Devendra K Agrawal1
1Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.
Archives of Internal Medicine Research
|February 4, 2025
Summary
Semaglutide effectively manages Type 2 Diabetes Mellitus, aids weight loss, and reduces cardiovascular risks. However, potential adverse effects and drug interactions require careful consideration for safe patient use.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 Diabetes Mellitus (T2DM) management has advanced with new therapeutic classes.
- Semaglutide represents a significant development in T2DM pharmacotherapy.
Purpose of the Study:
- To review the mechanism of action, formulation, benefits, contraindications, adverse effects, and drug interactions of semaglutide.
- To explore the potential repurposing of semaglutide in other conditions like Alzheimer's disease and polycystic ovary syndrome.
Main Methods:
- Comprehensive literature review of semaglutide's pharmacological properties and clinical applications.
- Analysis of efficacy data for glycemic control, weight management, and cardiovascular risk reduction.
- Evaluation of safety profiles, including adverse events, contraindications, and drug interactions.
Main Results:
- Semaglutide demonstrates efficacy in improving glycemic control, promoting weight loss, and reducing cardiovascular risks in T2DM patients.
- Potential benefits observed in Alzheimer's disease and polycystic ovary syndrome due to anti-neuroinflammatory effects.
- Identified adverse effects include pancreatitis, kidney injury, gallbladder issues, and anesthetic risks; contraindications include MTC/MEN2 and pregnancy.
Conclusions:
- Semaglutide is an effective therapy for T2DM with broader potential applications.
- Careful consideration of adverse effects, contraindications, and drug interactions is crucial for patient safety.
- Further research is needed to understand anesthetic risks and explore semaglutide's role in neurodegenerative diseases.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
01:06Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:15Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
01:16Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162